Twenty years of failure in NASH drug development ended in March 2024 when resmetirom (Rezdiffra) crossed the FDA finish line — the first approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis with liver fibrosis. That approval didn't slow down the field; it validated it. The MASH pipeline now has over 30 molecules in Phase 2/3 testing different mechanisms, GLP-1 agonists are generating compelling liver data as a byproduct of their metabolic work, and hepatitis B researchers are finally talking seriously about functional cure rather than indefinite viral suppression. For patients sitting with an F2 or F3 fibrosis score wondering what's next, there has never been more to discuss with a hepatologist.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Resmetirom (Rezdiffra) became the first FDA-approved drug for MASH with liver fibrosis in March 2024, based on MAESTRO-NASH Phase 3 data showing 26–29% MASH resolution and 24–26% fibrosis improvement at 52 weeks vs. 10% and 14% for placebo respectively. The pipeline now includes semaglutide (ESSENCE Phase 3: 62.9% MASH resolution vs. 34.3% placebo), efruxifermin (SYNCHRONY Phase 3actively recruiting), and lanifibranor (NATIVE Phase 3 results in). On the hepatitis B front, RNAi agents and capsid assembly modulators are in combination trials chasing functional cure — a goal that suppressive antivirals alone have never come close to achieving.
ClinicalMetric Analysis
- MASH biopsy as the regulatory endpoint is the biggest logistical barrier to trial enrollment — and its days as the gold standard are numbered. Liver biopsy has 10–20% sampling variability, requires procedure room access, and is invasive enough that many otherwise eligible patients decline. Non-invasive biomarker strategies — MRI-PDFF for steatosis, ELF score for fibrosis, and serum cytokeratin-18 fragments for hepatocyte apoptosis — are in regulatory dialogue with FDA as surrogate endpoints. The trials that validate these as reliable surrogates will enable much larger Phase 3 programs and broaden enrollment beyond highly motivated academic center patients.
- Semaglutide's ESSENCE trial MASH results (62.9% resolution) should be contextualized by patient selection. ESSENCE enrolled F2–F3 fibrosis patients — the subgroup most likely to show biopsy-measurable improvement. F1 patients may not need pharmacological intervention at that stage; F4 patients (cirrhosis) represent a different disease phase where semaglutide's fibrosis benefit is less certain. Applying the 62.9% figure to all MASH patients overstates what's been demonstrated.
- HBV functional cure requires eliminating cccDNA — the target that 30 years of nucleoside analogue development hasn't touched. Entecavir and tenofovir suppress viral replication to undetectable levels, but covalently closed circular DNA persists in hepatocyte nuclei and restarts replication if antivirals stop. RNAi agents and capsid assembly modulators reduce cccDNA formation and surface antigen production, but achieving HBsAg loss likely requires concurrent immune reconstitution to clear existing infected cells. The functional cure trials combining two or three mechanisms are asking a harder biological question than anything prior HBV therapy has attempted.
The Post-Resmetirom MASH Pipeline
Resmetirom works as a liver-selective thyroid hormone receptor beta agonist — it accelerates hepatic fatty acid oxidation without the systemic thyrotoxic effects of a non-selective thyroid agonist. MAESTRO-NASH enrolled 966 patients with biopsy-confirmed MASH and showed dose-dependent effects: at 100mg, 26% achieved MASH resolution vs. 10% for placebo; fibrosis improvement of at least one stage ran 24–26% vs. 14% for placebo. Modest absolute numbers, but in hepatology, where nothing had worked for two decades, they were enough.
What makes the 2026 pipeline genuinely interesting is mechanistic diversity. Each of the leading programs attacks the same endpoint — MASH resolution and fibrosis improvement — through completely different biology:
- Semaglutide 2.4mg (ESSENCE Phase 3): The headline number was remarkable — 62.9% MASH resolution without fibrosis worsening vs. 34.3% for placebo. GLP-1 receptor agonism reduces hepatic lipogenesis, drives substantial weight loss, and improves insulin sensitivity, which collectively unloads the liver of the metabolic stress driving MASH. FDA review for the liver indication is underway.
- Efruxifermin (FGF21 analog, SYNCHRONY Phase 3): FGF21 is a hepatokine that regulates lipid and glucose metabolism. Phase 2b data showed 39% achieved fibrosis improvement ≥1 stage vs. 20% for placebo in F2–F3 patients — and the F4 cirrhosis subgroup showed signals that are driving the dedicated cirrhosis trial. SYNCHRONY-NASH Phase 3 is actively recruiting.
- Lanifibranor (pan-PPAR agonist, NATIVE Phase 3): Activates PPAR alpha, gamma, and delta simultaneously — targeting steatosis, inflammation, and fibrosis through three different nuclear receptor pathways. NATIVE showed significant NASH resolution and fibrosis improvement; regulatory submission is underway in Europe and the US.
- Combination strategies: GLP-1 + FXR agonist and GLP-1 + FGF21 combination Phase 2 trials are testing whether synergistic fibrosis regression is achievable when you attack metabolism and stellate cell activation simultaneously. The data so far is encouraging but immature.
Cirrhosis: What the Fibrosis Regression Data Actually Shows
The conventional assumption that F4 cirrhosis is irreversible has been eroding for years. Several cohort studies and MASH trial subgroup analyses have documented histological fibrosis regression in cirrhotic patients who achieved sufficient metabolic improvement — the liver has more regenerative capacity than the classic pathology teaching suggested. Whether drug-induced MASH resolution can reliably produce meaningful cirrhosis regression is the central open question for this decade.
For advanced fibrosis and cirrhosis trials specifically, hepatic venous pressure gradient (HVPG) is increasingly used as a primary endpoint rather than biopsy alone — it's more sensitive for detecting portal hypertension changes and feasible to repeat serially. The carvedilol data (CARVEDILOL-PREBIOP trial) validated this non-selective beta blocker for HVPG reduction in patients with clinically significant portal hypertension ≥10 mmHg, generating renewed interest in portal pressure-lowering as a standalone cirrhosis outcome. Drugs targeting activated hepatic stellate cells — the myofibroblast-like cells producing collagen — include FGF19 analogs (aldafermin) and several novel anti-fibrotic antibodies in Phase 2.
Hepatitis B Functional Cure: How Close Are We Really?
296 million people carry chronic hepatitis B. Current first-line antivirals — tenofovir alafenamide and entecavir — suppress HBV DNA to undetectable in the majority of patients, but they don't clear HBsAg. Functional cure (sustained HBsAg loss off treatment) occurs in roughly 1% of patients per year on nucleoside analogs. That's the problem the new mechanism classes are trying to solve.
- RNA interference (JNJ-3989, VIR-2218, AB-729): siRNA agents that degrade HBV RNA, reducing all viral proteins including HBsAg. Phase 2 data with JNJ-3989 showed HBsAg reductions of 2–3 log in combination with nucleoside analogs. Clinically meaningful, but sustained clearance after stopping therapy hasn't been reliably achieved yet. The hypothesis is that deep HBsAg suppression by RNAi agents restores immune tolerance and allows the immune system to finally clear infected hepatocytes.
- Capsid assembly modulators (CAMs, e.g., JNJ-56136379): These drugs disrupt HBV core protein assembly, blocking formation of the pgRNA-containing nucleocapsid required for cccDNA replenishment. Targeting cccDNA itself — the nuclear reservoir of HBV template — remains the hardest unsolved problem; CAMs don't directly degrade it but may starve it of replenishment over time.
- Finite treatment combination trials: RNAi + CAM + nucleoside analog for 48–96 weeks is the current target regimen. Phase 2 combination results reporting in 2026 show HBsAg loss rates in the 3–8% range sustained off-treatment — meaningfully better than nucleoside analogs alone but below where the field hoped to be by now.
The honest read: functional cure is closer than it was five years ago, but it's not arriving in 2026. The data remains preliminary, the optimal combination hasn't been identified, and durability requires years of follow-up. What has changed is that the goal is no longer theoretical — it's a question of regimen optimization.
Who Qualifies for Liver Disease Trials
MASH trials typically require biopsy-confirmed diagnosis within the past 24 months — NAS score ≥4 with fibrosis stage F2–F3 for most Phase 3 programs (some include F1b). Elevated ALT, confirmed hepatic steatosis on imaging, and absence of other chronic liver diseases (autoimmune hepatitis, PBC, PSC, significant alcohol use) are standard. Patients with F4 cirrhosis are usually excluded from MASH resolution studies but may qualify for dedicated cirrhosis or portal hypertension trials.
Hepatitis B cure trials require: HBsAg positive ≥6 months, quantitative HBsAg and HBV DNA at screening, stable nucleoside analog therapy for most combination studies, no decompensated cirrhosis, and no hepatocellular carcinoma. Co-infection with HDV excludes patients from HBV-specific programs — HDV is a separate research track. Active significant alcohol use is universally excluded across all liver disease trial programs.